Javelin Pharmaceuticals Announces 15 Percent Reduction in Workforce. News.
Monday, November 17th, 2008"We have infatuated difficult, but unavoidable actions, to modify secure costs across the institution to preserve and extend valuable development dollars. Todays organizational changes are being effected in weather of our priorities to column lofty quality regulatory submissions in the US and the EU for Dyloject and Ereska in 2009 and consummate affluent commercialization partnerships for our dilatory grade acute slang Pain in the arse Care Product portfolio," said Martin Driscoll, CEO of Javelin Pharmaceuticals. Mr. Driscoll continued, "We comprehend the commitment and whilom efforts of those employees spurious by todays notification and thank them for their contributions in help Javelin attain its first commodity approval and launch in a major western market.
The Company will provender additional details on its progression and tariff efficiency measures on its 2008 year-end results meeting call. About Javelin Pharmaceuticals, Inc.: With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to manifest reborn drugs and improved formulations of existing drugs to end unmet and underserved medical needs in the soreness supervision market. The Company has one marketed hypnotic in the UK and three medicament candidates in US Phase 3 clinical development.
